ºÚÁÏÍø

Biography

During my work as a graduate student in Dr. Richard A. Glennon’s lab my dissertation work involved design and synthesis of first generation selective allosteric modulators of nicotinic receptors in the CNS. As a research fellow we were the first to conduct thorough structure-activity relationship studies on the principle components of ‘Bath salts’/Zombie drugs which were a new sensation in late 2013. I am currently doing my postdoctoral work in Dr. Terry W. Moore’s lab at University of Illinois at Chicago. I am currently involved in synthesis and biological evaluation of small molecule inhibitors for Keap1/Nrf2 interaction. The potential use of these agents could be as anti-cancer, anti-inflammatory, anti-diabetic and for various CNS disorders. The second project involves synthesis of stapled peptides to disrupt the complex between Estrogen receptors and various co-activator complexes which can be a potential therapeutic treatment for ER+ve breast cancer.

Research Interest

The following project summaries allows me to briefly elaborate on my medicinal chemistry and drug design expertise. I am adept with various scaffold synthesis such as, halogen-containing indoles, phenylalkylamines, sulfonamides of quinoline, 1,2,3,4-tetrahydroquinoline, and isoquinoline substituents. I am experienced in handling and performing pyrophoric reactions, organometallic reaction, hydrogenation reaction under par hydrogenator, coupling reaction using coordinated metal complexes, and various aromatic substitution reactions. Experienced in complete purification and characterization of target molecule using CombiFlash, preparative HPLC, flash column chromatography, NMR (1H, 13C, DEPTq and NOE), HPLC (Shimadzu), LCMS (Shimadzu), HRMS (IT-TOF). I have experience in performing fluorescence based assay using Biotek Synergy S4 biochemical characterization of target molecules.

Certificate

Global Speakers in the subject

Global Experts in the subject